Capricor Therapeutics Inc (NASDAQ:CAPR) Short Interest Update

Capricor Therapeutics Inc (NASDAQ:CAPR) was the recipient of a significant growth in short interest in the month of November. As of November 30th, there was short interest totalling 4,410,000 shares, a growth of 14.5% from the November 15th total of 3,850,000 shares. Based on an average daily trading volume, of 3,430,000 shares, the short-interest ratio is currently 1.3 days.

Capricor Therapeutics Trading Up 5.8 %

CAPR stock traded up $0.77 during trading on Monday, hitting $14.03. 949,684 shares of the stock traded hands, compared to its average volume of 1,181,458. The stock has a market cap of $637.94 million, a price-to-earnings ratio of -13.58 and a beta of 3.98. Capricor Therapeutics has a one year low of $3.52 and a one year high of $23.40. The company has a 50 day simple moving average of $18.42 and a 200 day simple moving average of $10.07.

Insider Activity at Capricor Therapeutics

In other Capricor Therapeutics news, major shareholder Shinyaku Co Ltd Nippon bought 2,798,507 shares of Capricor Therapeutics stock in a transaction on Friday, September 20th. The stock was purchased at an average cost of $5.36 per share, for a total transaction of $14,999,997.52. Following the completion of the purchase, the insider now directly owns 7,090,351 shares of the company’s stock, valued at $38,004,281.36. The trade was a 65.21 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 12.00% of the stock is owned by insiders.

Hedge Funds Weigh In On Capricor Therapeutics

Large investors have recently modified their holdings of the stock. Main Street Financial Solutions LLC increased its stake in shares of Capricor Therapeutics by 37.5% in the 2nd quarter. Main Street Financial Solutions LLC now owns 27,500 shares of the biotechnology company’s stock valued at $131,000 after buying an additional 7,500 shares during the period. SG Americas Securities LLC acquired a new stake in Capricor Therapeutics in the third quarter worth about $133,000. Bank of New York Mellon Corp lifted its position in Capricor Therapeutics by 12.8% during the 2nd quarter. Bank of New York Mellon Corp now owns 79,782 shares of the biotechnology company’s stock valued at $381,000 after purchasing an additional 9,040 shares during the period. The Manufacturers Life Insurance Company bought a new position in shares of Capricor Therapeutics in the 3rd quarter valued at about $161,000. Finally, Sassicaia Capital Advisers LLC acquired a new position in Capricor Therapeutics in the third quarter valued at approximately $192,000. 21.68% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

CAPR has been the topic of several analyst reports. Cantor Fitzgerald increased their price target on Capricor Therapeutics from $25.00 to $30.00 and gave the company an “overweight” rating in a report on Thursday, November 14th. Piper Sandler started coverage on shares of Capricor Therapeutics in a research note on Monday, October 21st. They set an “overweight” rating and a $35.00 target price for the company. Oppenheimer restated an “outperform” rating and set a $15.00 price objective on shares of Capricor Therapeutics in a report on Monday, September 23rd. HC Wainwright reissued a “buy” rating and set a $77.00 target price on shares of Capricor Therapeutics in a research report on Thursday, November 14th. Finally, Maxim Group lifted their price target on shares of Capricor Therapeutics from $12.00 to $25.00 and gave the stock a “buy” rating in a research note on Wednesday, September 25th. One equities research analyst has rated the stock with a sell rating and six have issued a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $34.50.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.